Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 11, 2007 Brian Lawler	The MGI Deal Makes Sense MGI Pharma announces it is being acquired by Japanese pharma giant Eisai for $3.9 billion.
The Motley Fool July 24, 2007 Brian Lawler	MGI Flies Shares of MGI Pharma rise after positive second-quarter results and a bright outlook for the coming months.
The Motley Fool September 3, 2004 Charly Travers	MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions.
The Motley Fool July 3, 2008 Brian Lawler	Celgene Savors the Schadenfreude Bad news for a rival is a bonanza for drugmaker Celgene.
The Motley Fool October 18, 2007 Brian Lawler	MGI's Quiet Gains The specialty pharma notches a healthy third-quarter and should keep performing well into the future. Investors, take note.
The Motley Fool October 23, 2006 Brian Lawler	MGI's Anonymous Growth If there's a value stock in the pharma world, this may be it.
The Motley Fool December 4, 2007 Brian Lawler	Another Drug Deal Goes Down Canadian specialty pharma Axcan Pharma became the latest drugmaker to be acquired by a private equity group -- for $1.3 billion in cash.
The Motley Fool December 7, 2007 Brian Lawler	Drugmakers Gear Up for ASH Cancer-focused drugmakers will be presenting their most promising data at two premiere medical conferences. Investors, take note.
The Motley Fool October 6, 2010 Brian Orelli	Celgene Is All Grown Up An acquirer is on the prowl.
The Motley Fool November 8, 2007 Brian Lawler	Let the Biogen Bidding Begin Speculation of bidding by big-pharma companies for Biogen IDEC cause the shares to rise. Investors, take note.
The Motley Fool August 29, 2008 Brian Lawler	Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity?
The Motley Fool November 20, 2007 Brian Orelli	Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future.
The Motley Fool January 29, 2010 Brian Orelli	Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead.
The Motley Fool August 6, 2007 Brian Orelli	Hopeful Investors Stoke Pharmion's Price Clinical trials to get a drug approved for new uses usually don't have the gusto that trials for the original New Drug Application have, but Pharmion results released last week have blown the stock price through the roof.
The Motley Fool June 2, 2010 Brian Orelli	Take Your Low Margins and Shove 'Em In an effort to help lower its budget problems, Greece told drugmakers it was slashing prices of drugs, take it or leave it. Novo Nordisk chose "leave it."
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool May 20, 2004 W.D. Crotty	$1 Billion Pharmion? The specialty drug company's stock soars on the FDA's approval of a drug that treats a blood condition.
The Motley Fool December 21, 2010 Brian Orelli	4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool December 31, 2010 Brian Orelli	How the Other Half of Pharma Lives A dive into spec pharma.
BusinessWeek March 12, 2007 Gene G. Marcial	SuperGen Is Looking Healthier Biotechs are gaining traction this year as fund managers discover many with viable products that are still underpriced.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool November 12, 2009 Brian Orelli	The Life-and-Death Situation That Isn't Branded-drug makers aren't playing fair because they refuse to sell samples to generic drug makers.
The Motley Fool October 16, 2006 Brian Lawler	MGI Drug Approval Falters The FDA gives the thumbs-down to Saforis. However, investors should take notice of this well-run pharmaceutical.
The Motley Fool December 28, 2007 Brian Orelli	Investing in a Purchased Company Billionaire investor Steven Cohen, through his hedge fund SAC Capital Advisors, ups his stake in biotech company Pharmion. Let's take a look at why.
The Motley Fool May 26, 2009 Brian Orelli	Buy Now! It Might Get Bought! Clinical trial results and FDA approvals ultimately drive any increase in drugmakers' value. That's what pharmaceutical investors should focus on. The potential for an acquisition should be nothing more than icing on the cake.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool January 18, 2005 Charly Travers	Biotech Class of 2004 Hot drugs are leading to amazing stock performances. CoTherix... Eyetech Pharmaceuticals... Pharmion... etc.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool April 29, 2011 Brian Orelli	Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves.
The Motley Fool May 7, 2010 Brian Orelli	Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool January 11, 2010 Brian Orelli	Celgene Revs Up for a New Year Preliminary 2009 sales released at the J.P. Morgan Health Care Conference have sales up about 20% year over year and Celgene is guiding for 20% revenue growth next year as well.
BusinessWeek August 9, 2004 Gene G. Marcial	MGI Pharma Has Just What Patients Need Its first major drug, an injection to prevent chemotherapy-induced nausea and vomiting, is on fire in a $1.5 billion market. And turning MGI into a moneymaker.
The Motley Fool August 7, 2008 Brian Orelli	The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
The Motley Fool August 17, 2007 Brian Lawler	The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition.
BusinessWeek September 4, 2006 Gene G. Marcial	A Super Outlook For SuperGen Biotechs have not fared well in this fickle market.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool December 31, 2007 Brian Lawler	The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007.
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
The Motley Fool January 31, 2011 Brian Orelli	Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities.
The Motley Fool January 28, 2008 Brian Lawler	A Great Way to Recession-Proof Your Portfolio If you want a recession resistant portfolio, invest in large cap pharmaceuticals.
Pharmaceutical Executive December 1, 2008 Walter Armstrong	The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.
The Motley Fool November 4, 2011 Luke Timmerman	Celgene to Pump $45M Into Quanticel to Discover Cancer Drugs Celgene strikes an unusual agreement.
The Motley Fool June 30, 2011 Brian Orelli	Biotech Winners of a Repatriation Holiday Biotechs and dividend players will come out ahead.
The Motley Fool March 30, 2010 Brian Orelli	Your Biotech's Cash Burn Just Went Down Tucked inside the hundreds of pages of the health-care reform bill, is a nice little bonus for a select group of drugmakers.
The Motley Fool July 10, 2008 Brian Lawler	Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks.